Noxopharm Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NOX.AX research report →
Price Chart
About the company
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors.
- CEO
- Olivier Laczka
- IPO
- 2016
- Employees
- 8
- HQ
- Glenhaven, NSW, AU
Get TickerSpark's AI analysis on NOX.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.88M
- P/E
- -5.00
- PEG
- 0.05
- P/S
- 17.35
- P/B
- -24.36
- EV/EBITDA
- -5.38
- Div Yield
- 0.00%
- Gross Margin
- -63.20%
- Op Margin
- -532.32%
- Net Margin
- -329.78%
- ROE
- 2509.60%
- ROIC
- -149.71%
Latest fiscal year · YoY change
- Revenue
- $2.82M+17.5%
- Gross Profit
- $-1,445,645-170.3%
- Op Income
- $-9,651,306
- Net Income
- $-4,884,170-36.5%
- EPS
- $-0.02-36.9%
- OCF Growth
- -751.2%
- FCF Growth
- -751.2%
- 52W High
- $0.12
- 52W Low
- $0.05
- 50D MA
- $0.08
- 200D MA
- $0.08
- Beta
- 0.00
- RSI (14)
- 59
- Avg Volume
- 181.88K
No earnings-call transcripts are available for NOX.AX yet.
- Free Float
- 97.4%
- Shares Outstanding
- 307.24M
- Float Shares
- 299.34M
Our NOX.AX coverage
Recent articles, reports, and earnings notes.
No research on NOX.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NOX.AX report →